Neuroendocrine Tumor Market
Global Neuroendocrine Tumor Market Size, Share & Trends Analysis Report by Treatment Type (Somatostatin Analogs (SSA), Targeted Therapy, Chemotherapy, and Others), By Indication (Lungs, Pancreas, Gastrointestinal, and Others), By End-User (Hospital & Clinics and Others), Forecast 2019-2025
The global neuroendocrine tumor market is projected to grow at a CAGR of around 10% during the forecast period. The increased prevalence of the neuroendocrine tumor is generating the scope for the market growth. There are around 1 million cases of neuroendocrine tumors across the globe which is projected to increase in the future due to the sedentary lifestyles. Further, the rising prevalence of neuroendocrine tumors enhances the adoption rate of the drugs for the treatment of the disease, which in turn supports the market growth. However, the cost of the manufacturing of the drugs is higher as compared to other drugs which is likely to hinder the growth of the market in the near future.
In addition, rising government initiatives, supports,and funding by various international organizations which is further projected to boost the market growth during the forecast period. Ongoing research activities regarding the development of novel drugs are also supporting the market growth. For instance, in 2018, the Neuroendocrine Tumor Research Foundation (NETRF), invested around $1.5 million for the production of Peptide Receptor Radionuclide Therapy (PRRT). Moreover, a novel drug produced by Progenics Pharmaceuticals Inc. is under clinical trials, PSMA Targeted PET Imaging Agent for the treatment of prostate cancer. Thus, heavy investments by the key players and cancer research organizations are propelling market growth.
Segmental Outlook
The global neuroendocrine tumor market is segmented on the basis of treatment type, indication, and end-user. Based on the treatment type, the market is segmented as somatostatin analogs (SSA), targeted therapy, chemotherapy, and others. Based on indication, the market is segmented into lungs, pancreas, gastrointestinal, and others. Based on the end-user, the market is segmented into hospital clinics and others.
Hospitals & Clinics Segment is Projected to Hold Considerable Share in the Market Growth
Amongst the end-users of the market, the hospitals& clinics segment is expected to hold a significant share in the market. The segmental growth is accredited to the availability of advanced healthcare systems. Various facilities are needed to provide to the patients in the hospitals and to offer those, companies offer various products customized for the hospitals. Initially, most of the products and devices in the healthcare sector are designed for hospitals only. However, after the successful implementation of the devices, the companies started manufacturing products for other facilities to offer better treatment options at affordable healthcare costs, and to reduce the patient load on the hospitals.
Global Neuroendocrine Tumor Market by End-User, 2018 (%)
Regional Outlook
The global neuroendocrine tumor is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to hold a significant share in the global neuroendocrine tumors market. The regional growth is attributed to the increased number of cases in the regions. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. An additional 3,000 neuroendocrine tumors (NETs) are diagnosed annually. In addition, the region has a well-developed healthcare infrastructure which further gives a boost to the regional growth of the market.
Whereas, in the Asia-Pacific region, the rising healthcare spending, improving infrastructure, and rising standards of living are projected to drive growth during the forecast period. China, India, Japan, Australia, Korea, and Taiwan are the key regions growing at a significant rate, which contributes to the regional market growth. The European region is also projected to grow significantly in the global neuroendocrine tumors market as the countries such as UK and Germany are indulged in various R&D activities for the development of drugs for several treatment types.
Global Neuroendocrine Tumor Market by Region 2018, (%)
Market Players Outlook
Some of the prominent players operating in the global neuroendocrine tumor market include Boehringer Ingelheim International GmbH, Eli Lilly & Co., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Progenics Pharmaceuticals, Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and others. The market players are adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others in order to thrive in a competitive environment. In addition, the players are investing in R&D for the development of new treatment options. For instance, In June 2018, Boehringer Ingelheim invested$270 million for the manufacturing of novel Biologicals Development Center (BDC) specialized for the immunology and immune-oncology sector. Such investment and initiatives are projected to boost the market growth during the forecast period.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neuroendocrine tumors market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Neuroendocrine Tumor Market by Treatment Type
5.1.1. Somatostatin Analogs (SSA)
5.1.2. Targeted Therapy
5.1.3. Chemotherapy
5.1.4. Others
5.2. Global Neuroendocrine Tumor Market by Indication
5.2.1. Lungs
5.2.2. Pancreas
5.2.3. Gastrointestinal
5.2.4. Others
5.3. Global Neuroendocrine Tumor Market by End-User
5.3.1. Hospital& Clinics
5.3.2. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AVEO Pharmaceuticals Inc.
7.2. Boehringer Ingelheim International GmbH
7.3. Bristol-Myers Squibb Co.
7.4. Dauntless Pharmaceuticals, Inc.
7.5. Eli Lilly & Co.
7.6. Exelixis, Inc.
7.7. F. Hoffmann-La Roche Ltd.
7.8. Hutchison MediTechLtd.
7.9. Ipsen Group
7.10. Mateon Therapeutics, Inc.
7.11. Novartis International AG
7.12. Pfizer Inc.
7.13. Progenics Pharmaceuticals, Inc.
7.14. Tarveda Therapeutics, Inc.
7.15. Teva Pharmaceutical Industries, Ltd.
1. GLOBAL NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
2. GLOBAL SOMATOSTATIN ANALOGS FOR NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL TARGETED THERAPY FOR NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL CHEMOTHERAPY FOR NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL OTHERTREATMENT FOR NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY INDICATION, 2018-2025 ($ MILLION)
7. GLOBAL NEUROENDOCRINE TUMOR AT LUNGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL NEUROENDOCRINE TUMOR AT PANCREAS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL NEUROENDOCRINE TUMOR AT GASTROINTESTINAL MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL NEUROENDOCRINE TUMOR FOR OTHER INDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
12. GLOBAL NEUROENDOCRINE TUMOR IN HOSPITALS& CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL NEUROENDOCRINE TUMOR IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
14. GLOBAL NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
15. NORTH AMERICAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. NORTH AMERICAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
17. NORTH AMERICAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY INDICATION, 2018-2025 ($ MILLION)
18. NORTH AMERICAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
19. EUROPEAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
20. EUROPEAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
21. EUROPEAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY INDICATION, 2018-2025 ($ MILLION)
22. EUROPEAN NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
23. ASIA-PACIFIC NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
24. ASIA-PACIFIC NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
25. ASIA-PACIFIC NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY INDICATION, 2018-2025 ($ MILLION)
26. ASIA-PACIFIC NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
27. REST OF THE WORLD NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
28. REST OF THE WORLD NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY INDICATION, 2018-2025 ($ MILLION)
29. REST OF THE WORLD NEUROENDOCRINE TUMOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
1. GLOBAL NEUROENDOCRINE TUMOR MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
2. GLOBAL NEUROENDOCRINE TUMOR MARKET SHARE BY INDICATION, 2018 VS 2025 (%)
3. GLOBAL NEUROENDOCRINE TUMOR MARKET SHARE BY END-USER, 2018 VS 2025 (%)
4. GLOBAL NEUROENDOCRINE TUMOR MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
5. US NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
7. UK NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
8. FRANCE NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
9. GERMANY NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
10. ITALY NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
11. SPAIN NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
12. ROE NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
13. INDIA NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
14. CHINA NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
15. JAPAN NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF ASIA-PACIFIC NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
17. REST OF THE WORLD NEUROENDOCRINE TUMOR MARKET SIZE, 2018-2025 ($ MILLION)
